Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 7/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 5/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12434268 | 0.81 | CNR1 (0.68) | KCNA5NPC1RAB9ACNR1SMN1; SMN2 | |
| SCHEMBL12434255 | 0.78 | KCNA5 (0.54) | KCNA5NPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL2209542 | 0.77 | KCNA5 (1.00) | KCNA5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12434226 | 0.76 | KCNA5 (0.76) | KCNA5NPC1MAPK1ALDH1A1 | |
| SCHEMBL12434260 | 0.75 | CNR1 (0.54) | KCNA5CNR1 | |
| SCHEMBL12434263 | 0.75 | KCNA5 (0.55) | KCNA5NPC1RAB9ACNR1NAMPT | |
| SCHEMBL12434243 | 0.75 | KCNA5 (0.61) | KCNA5NPC1RAB9ACNR1 | |
| SCHEMBL4242287 | 0.72 | KCNA5 (0.66) | KCNA5NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL13789528 | 0.72 | KCNA5 (0.52) | KCNA5NPC1RAB9ACNR1 | |
| SCHEMBL2208589 | 0.72 | KCNA5 (0.68) | KCNA5NPC1RAB9ACNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7982045-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-7982045-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-07-30 | — | — | US | disclosed |
| US-7514582-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
| US-7514582-B2 | 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192096-A1 | 2'-Substituted 1,1'-Biphenyl-2-Carboxamides, Processes For Their Preparation, Their Use As Medicaments, And Pharmaceutical Preparations Comprising Them | MLLT3, RYR2, CACNA1E | KCNA5 90/4885NPC1 3604/4885RAB9A 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.